| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| jnj-26483327 | epidermal growth factor receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.08 | phase 1 | inhibitor |
| jnj-26483327 | epidermal growth factor receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.08 | phase 1 | unknown |
| jnj-26483327 | erbb2 tyrosine kinase receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.09 | phase 1 | unknown |
| jnj-26483327 | erbb2 tyrosine kinase receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.09 | phase 1 | inhibitor |
| jnj-26483327 | erbb4 tyrosine kinase receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.19 | phase 1 | inhibitor |
| jnj-26483327 | vascular endothelial growth factor receptor 3 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.16 | phase 1 | unknown |
| jnj-26483327 | vascular endothelial growth factor receptor 3 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.16 | phase 1 | inhibitor |
| jnj-26483327 | fyn tyrosine protein kinase | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.38 | phase 1 | inhibitor |
| jnj-26483327 | fyn tyrosine protein kinase | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.38 | phase 1 | unknown |
| jnj-26483327 | lck tyrosine protein kinase | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.24 | phase 1 | unknown |
| jnj-26483327 | lck tyrosine protein kinase | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.24 | phase 1 | inhibitor |
| jnj-26483327 | tyrosine-protein kinase lyn | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.33 | phase 1 | unknown |
| jnj-26483327 | tyrosine-protein kinase lyn | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.33 | phase 1 | inhibitor |
| jnj-26483327 | yes tyrosine kinase | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.07 | phase 1 | unknown |
| jnj-26483327 | yes tyrosine kinase | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.07 | phase 1 | inhibitor |
| click here to return to the previous page | ||||||||